CLYM Climb Bio Inc
Climb Bio, Inc., a clinical-stage biotechnology company, focuses on developing therapies to address unmet needs for patients living with immune-mediated diseases. The company's lead product candidate is the budoprutug, a…
Industry Peers
Biotechnology| Headline | Source | Time |
|---|---|---|
Older | ||
 The Biggest Losers In Biotech — And It Had Nothing To Do With 'Compelling,' 'Best-In-Disease' Data Biotech stocks widely slumped Wednesday, with Rapport Therapeutics, Climb Bio and Cullinan Therapeutics among some of the hardest-hit names. | ||
 Ionis’ rare neurology drug approved; Pfizer inks an ADC deal Zanvastro is now the first approved medicine for Alexander disease. Elsewhere, an immune system specialist posted positive results and a cell therapy developer turned to layoffs. | ||
 Why Climb Bio, Up 1,300% Over 17 Months, Just Took A Tumble Climb Bio reversed course downward Thursday despite potential "best-in-class" data for its experimental kidney disease treatment. | ||
 Climb Bio Phase I Data Backs 12-Week Dosing Plan for IgA Nephropathy Drug Climb Bio (NASDAQ:CLYM) presented phase I data for CLYM116, an anti-APRIL “sweeper” antibody being developed for IgA nephropathy, and said the results support advancing the program into an ongoing phase II study in China. The company said CLYM116 is designed to bind circulating APRIL, bring the tar | ||
 Climb Bio Shares Rise 17% After Phase 1 CLYM116 Trial Data Climb Bio, Inc. (NASDAQ:CLYM) shares rose 17% on Thursday after the clinical-stage biotechnology company released Phase 1 trial data for CLYM116, its anti-APRIL monoclonal antibody being developed for IgA nephropathy. | ||
 Climb Bio (CLYM) Advances Phase 2 Trial In China, Is The Valuation Already Priced In? Climb Bio (CLYM) is back in focus after Beijing Mabworks Biotech began dosing the first patient with immunoglobulin A nephropathy in a Phase 2 clinical trial in China, highlighting their joint development efforts. The clinical update arrives while Climb Bio’s share price has moved sharply, with a 1-month share price return of 38.94% and a 90-day share price return of 49.16%. This has contributed to a year-to-date share price return of 375.73% and a very large 1-year total shareholder return,... | ||
Do Climb Bio’s (CLYM) Mixed Loss Trends Reveal a Shifting Path to Sustainable Scale? Climb Bio, Inc. reported its second-quarter 2026 earnings, posting a net loss of US$13.5 million versus US$8.67 million a year earlier, while basic loss per share from continuing operations widened to US$0.18 from US$0.13. Over the first six months of 2026, however, Climb Bio’s net loss narrowed to US$27.22 million from US$29.45 million, with basic loss per share improving to US$0.38 from US$0.44, highlighting mixed progress on its financial profile. With these mixed earnings trends,... | ||